TCF7L2 Recombinant Rabbit Monoclonal Antibody (SC06-90)

* CHF, excl. 8.1% VAT and shipping costs

Product Description

Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire. TCF7L2, or TCF4, is a high mobility group (HMG) box-containing transcription factor that plays a key role in the Wnt signaling pathway. TCF7L2 has been implicated in glucose homeostasis through the regulation of pro-glucagon gene expression, which encodes glucagon-like peptide 1 (GLP-1). Genetic variants of TCF7L2 have been linked to type 2 diabetes, and it has specifically been shown to have an important role in the regulation of both beta-cell survival and function. Several splicing isoforms for TCF7L2 have been shown to be differentially expressed in tissues during cancer progression, and gene targeting studies indicate that TCF7L2 is required to maintain the crypt stem cells of the small intestine.